StockNews.AI
INSP
StockNews.AI
140 days

Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025

1. INSP will report Q1 2025 financial results on May 5. 2. A conference call will follow the earnings release at 5 p.m. ET. 3. Inspire’s therapy is FDA and EU approved for sleep apnea treatment.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report could show strong performance, similar to past quarters where positive results led to price increases. Investors often react favorably to timely communication and established product efficacy.

How important is it?

Earnings announcements often significantly influence stock prices; investors will closely analyze results and future guidance.

Why Short Term?

The earnings release and conference call may generate immediate market reactions based on performance metrics relevant to INSP.

Related Companies

APFHSLEEPAVAH
April 01, 2025 08:00 ET  | Source: Inspire Medical Systems MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Inspire's Q1 2025 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.  Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks. About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@inspiresleep.com 617-549-2443

Related News